Iovance Biotherapeutics, Inc.IOVANASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating

Buy

15 analysts·Moderate coverage

67%

Rating Distribution

Strong Buy

00%

Buy

1067%

Hold

533%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 446% higher.

Bear Case

$2.00

-23%

Consensus

$14.25

+446%

Bull Case

$40.00

+1433%

Price Range15 analysts

Low

Consensus

High

$2.00

$40.00

Current Target

Current Price

$2.61

Upside to Target

$11.64

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.59(7 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+44.39%

EPS—

FY2028

Rev+37.17%

EPS—

FY2029

Rev+18.31%

EPS+112.35%

Earnings Surprises

Beat rate:50%(6/12 quarters)

Avg surprise:+5.1%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

May 16, 2025UBS

Iovance Biotherapeutics downgraded to Neutral from Buy at UBS

Target:$2.00

+20.5%from $1.66

Feb 28, 2025Piper Sandler

Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler

Target:$6.00

+41.5%from $4.24

Jan 31, 2025Piper Sandler

Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler

Target:$7.50

+28.2%from $5.85

Oct 24, 2024UBS

UBS Starts Iovanace Biotherapeutics (IOVA) at Buy

Target:$17.00

+73.1%from $9.82

Aug 9, 2024Stifel Nicolaus

Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel

Target:$23.00

+479.3%from $3.97

Aug 9, 2024Robert W. Baird

Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird

Target:$24.00

+504.5%from $3.97

Jul 29, 2024Piper Sandler

Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral

Target:$10.00

+8.1%from $9.25

Jun 20, 2024JMP Securities

Iovance Biotherapeutics price target lowered to $23 from $25 at JMP Securities

Target:$23.00

+475.0%from $4.00

May 31, 2024Stifel Nicolaus

Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)

Target:$28.00

+530.6%from $4.44

Mar 14, 2024Piper Sandler

Iovanace Biotherapeutics (IOVA) PT Raised to $19 at Piper Sandler

Target:$19.00

+33.7%from $14.21

Dec 8, 2022Goldman Sachs

Iovance Biotherapeutics downgraded to Neutral from Buy at Goldman Sachs

Target:$6.00

-16.3%from $7.17

Nov 20, 2022Piper Sandler

Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler

Target:$11.00

+66.2%from $6.62

Aug 23, 2022Robert W. Baird

Iovance Biotherapeutics (IOVA) Stock: $25 Target And Outperform Rating

Target:$25.00

+334.8%from $5.75

Jul 1, 2022Goldman Sachs

Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18

Target:$18.00

+63.0%from $11.04

May 27, 2022Stifel Nicolaus

Stifel Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $13

Target:$13.00

+87.3%from $6.94

Apr 7, 2022Robert W. Baird

Iovance Biotherapeutics (IOVA) Stock: Why The Price Increased Today

Target:$34.00

+86.5%from $18.23

Apr 5, 2022Robert W. Baird

Iovance Biotherapeutics price target raised to $34 from $30

Target:$30.00

+81.2%from $16.56

Jan 28, 2022Stifel Nicolaus

Iovanace Biotherapeutics (IOVA) Stock: $25 Price Target From Stifel

Target:$25.00

+66.2%from $15.04

Jan 5, 2022Wells Fargo

Iovance Biotherapeutics price target lowered to $25 from $35 at Wells Fargo

Target:$25.00

+48.6%from $16.82

May 19, 2021Barclays

Iovance Biotherapeutics price target lowered to $40 from $60 at Barclays

Target:$40.00

+144.9%from $16.33

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance